AbbVie has reported full-year 2025 total revenue of USD 61.2 billion, an 8.6% year-on-year increase, with R&D investment reaching USD 9.1 billion. The company successfully navigated the patent expiry of Humira (adalimumab), which saw sales decline by 49.5% to USD 4.5 billion, through strong performance in its immunology, neuroscience and oncology franchises. The immunology segment, led by Skyrizi (risankizumab) and Rinvoq (upadacitinib), generated USD 30.4 billion, a 14% increase. Skyrizi sales surged 49.9% to USD 17.6 billion, solidifying its role as the new growth pillar.

The neuroscience segment grew 19.6% to USD 10.8 billion, driven by the migraine portfolio, including Qulipta (atogepant), which achieved blockbuster status. The oncology segment grew modestly by 1.5% to USD 6.7 billion, with the FRα ADC Elahere (mirvetuximab soravtansine), acquired via ImmunoGen, delivering a strong 44% growth to USD 690 million. AbbVie is advancing its pipeline with new indications for Rinvoq in vitiligo and is optimistic for 2026, forecasting adjusted diluted earnings per share between USD 14.37 and USD 14.57.

PharmCube's NextBiopharm® database shows that the company commenced 11 registrational trials last year alone. Click here to request a free trial for NextBiopharm®.